Skip to content
Veracyte® Investor Relations
Veracyte is a global diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of diagnostic tests leverages advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment.
The company’s tests in lung cancer, prostate cancer, breast cancer, thyroid cancer, bladder cancer, and idiopathic pulmonary fibrosis are available to patients and its renal cancer and lymphoma subtyping tests are in development, the latter as a companion diagnostic. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its genomic tests to patients worldwide. Veracyte is based in South San Francisco, California.

Veracyte® Investor Relations

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte, Inc. to Host Conference Call and Webcast to Discuss Third Quarter 2014 Financial Results on November 13, 2014
SOUTH SAN FRANCISCO, Calif. , Nov. 6, 2014 /PRNewswire/ -- Veracyte, Inc. (Nasdaq: VCYT) announced today that its third quarter 2014 financial results will be released after close of market on Thursday, November 13, 2014 .  Following the announcement, Veracyte's management will host a live
View HTML
Toggle Summary Veracyte, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2014 Financial Results on August 13, 2014
SOUTH SAN FRANCISCO, Calif. , Aug. 6, 2014 /PRNewswire/ --  Veracyte, Inc. (Nasdaq: VCYT) announced today that its second quarter 2014 financial results will be released after close of market on Wednesday, August 13 , 2014.  Following the announcement, Veracyte's management will host a live
View HTML

Events

There are currently no events to display.

Presentations

Title Documents

Corporate Presentation November 2022